Sera PrognosticsSERA
SERA logo
Fair Value
US$5
Share price17 Dec
US$1.9561.0% undervalued intrinsic discount
Loading
1Y-18.07%
7D-2.99%

Medicaid Expansion And Maternal Health Focus Will Drive Long-Term Opportunity In Preterm Birth Prevention

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
17 Dec 25
Views
8
Not Invested

Fair Value vs Share Price

US$5
vs US$1.9561.0% undervalued intrinsic discount
PastFuture-44m12m201920212023202520272028Revenue US$11.5mEarnings US$1.8m
394.8%
Revenue growth
16%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Sera Prognostics

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet with slight risk.

Market capUS$77.3m
PB1.3x
Estimated Growth58.9%
Dividend YieldN/A
Full analysis

CEO & management

Zhenya Lindgardt
CEO
3.3yrs
CEO Tenure

A women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.